Veeva Systems, which sells cloud software exclusively to drugmakers, reported fiscal second-quarter revenue of $928.0m on Wednesday afternoon, up 17.6% from a year earlier, and raised its full-year forecast to a range of $3,682m to $3,687m. It was the fourth consecutive quarter of accelerating growth, after 16.0%, 16.0% and 16.3%. Shares rose roughly 7% to 9% in after-hours trading.

The acceleration, though, came from the half of Veeva that has nothing to do with the story the company has been telling for three years. Veeva built its original business on customer-relationship software for pharmaceutical sales representatives, running on Salesforce's platform; it then spent years ripping that platform out and rebuilding the product as Vault CRM, forcing every large drugmaker through a migration. Completing that migration was supposed to be what reaccelerated commercial revenue. It has not, yet.

The mechanism test

Commercial subscription revenue grew 13% year over year in the quarter, below the 16% growth of total subscription revenue of $766.8m — meaning the research, development and quality half grew faster. Full-year guidance makes the split explicit: approximately $1,405m of commercial subscription revenue against roughly $1,675m from research, development and quality. Measured against last year's roughly $1,261m and $1,423m, disclosed in the fiscal 2026 results, that is about 11% growth for commercial and about 18% for the trials-and-regulatory side, which is now the larger half of the subscription base.

This is not a failing migration. Veeva reported more than 180 Vault CRM customers live, with Eli Lilly, Biogen and Regeneron among commercial wins. "AI is opening up the next big chapter for Veeva and life sciences. Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly," founder and chief executive Peter Gassner said in the August 26 release. But a record quarter of migrations is landing as customer counts, and part of even the modest commercial guidance increase this year was bought: of the $15m added at the first-quarter print, $10m came from the acquired Ostro brand-engagement platform.

Meanwhile the platform Veeva evicted is selling back into the same accounts. Salesforce says Agentforce Life Sciences is used by more than 140 organizations, double a year earlier, naming Novartis, Pfizer and Takeda among them; AstraZeneca selected it as its global customer-engagement platform in December 2025.

What the numbers earn

The profit side of the print is unambiguous. Operating income rose 40.4% to $275.0m on revenue up 17.6%, lifting operating margin to 29.6% from 24.8% — 4.8 percentage points of expansion, with gross margin flat at 75%. Billings grew 17.1% to $760.9m, ahead of recognized subscription revenue, which is what bookings running ahead of the revenue line looks like.

The shares are a different argument depending on where the clock starts. Over twelve months Veeva is down 13.9% while trailing gross profit grew 15.4%: price-to-gross-profit compressed from roughly 20.8x to 15.3x. Over the three months since late May the stock rose 55.7% — including single sessions above 8% on July 28 and August 13, and a 50-day average above the 200-day since August 11 — while trailing gross profit grew about 4%. Nearly all of that quarter's advance is a higher multiple, on a sector that has been rotating back into software after an artificial-intelligence-driven de-rating.

At 27.0x forward earnings against 39.4x trailing, the price embeds consensus earnings per share of $9.06 this fiscal year versus $5.44 last. Salesforce, growing 10.8%, trades near 18.7x trailing. The vertical premium is intact, and Veeva's own moat argument — its software is the system of record for regulatory submissions, so switching costs run in years — supports it.

The verdict

What the business earns is the operating leverage and the beat: growth is running ahead of the forward curve, since analysts model 15.1% for this year. What it does not yet earn is the specific bet. The commercial migration was the hedge in the story — the reason a life-sciences vendor could grow through a slowing software cycle — and it is currently the slower line, guided to roughly a third less growth than trials and quality. Artificial intelligence is the other pillar, and Veeva's agents were free to early adopters with general-release pricing targeted for 2027. IQVIA, the life-sciences data and research group, already quantifies its own: "We now have 294 agents deployed across 90 use cases," chairman and chief executive Ari Bousbib told investors on July 28.

That leaves Veeva priced for an acceleration it has so far delivered from clinical trials and regulatory workflows rather than from the field force. The 180 customers live on Vault CRM are the receipt for a migration; the invoice has not been written yet.